scholarly journals A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation

2018 ◽  
Vol 93 (4) ◽  
pp. E96-E98
Author(s):  
Dipenkumar Modi ◽  
Zaid Al-Kadhimi ◽  
Wei Chen ◽  
Hyejeong Jang ◽  
Abhinav Deol ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Phase Ii ◽  
Graft Versus Host Disease ◽  
Hematopoietic Cell Transplantation ◽  
Phase Ii Study ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Related Donor

Impact of decontamination therapy on gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic cell transplantation in children

2021 ◽  
Vol 69 (3) ◽  
pp. 103298
Author(s):  
Przemysław Gałązka ◽  
Jan Styczyński ◽  
Krzysztof Czyżewski ◽  
Małgorzata Salamonowicz-Bodzioch ◽  
Jowita Frączkiewicz ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Impact of Defibrotide in the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

2022 ◽  
pp. 106002802110681
Author(s):  
Rémi Tilmont ◽  
Ibrahim Yakoub-Agha ◽  
Nassima Ramdane ◽  
Micha Srour ◽  
Valérie Coiteux ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Control Group ◽  
Unrelated Donor ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Background Defibrotide is indicated for patients who develop severe sinusoidal obstructive syndrome following allogeneic hematopoietic cell transplantation (allo-HCT). Preclinical data suggested that defibrotide carries a prophylactic effect against acute graft-versus-host disease (aGVHD). Objective The purpose of this study was to investigate the effect of defibrotide on the incidence and severity of aGVHD. Methods This single-center retrospective study included all consecutive transplanted patients between January 2014 and December 2018. A propensity score based on 10 predefined confounders was used to estimate the effect of defibrotide on aGVHD via inverse probability of treatment weighting (IPTW). Results Of the 482 included patients, 64 received defibrotide (defibrotide group) and 418 did not (control group). Regarding main patient characteristics and transplantation modalities, the two groups were comparable, except for a predominance of men in the defibrotide group. The median age was 55 years (interquartile range [IQR]: 40-62). Patients received allo-HCT from HLA-matched related donor (28.6%), HLA-matched unrelated donor (50.8%), haplo-identical donor (13.4%), or mismatched unrelated donor (7.0%). Stem cell source was either bone marrow (49.6%) or peripheral blood (50.4%). After using IPTW, exposure to defibrotide was not significantly associated with occurrence of aGVHD (HR = 0.97; 95% CI 0.62-1.52; P = .9) or occurrence of severe aGVHD (HR = 1.89, 95% CI: 0.98-3.66; P = .058). Conclusion and Relevance Defibrotide does not seem to have a protective effect on aGVHD in patients undergoing allo-HCT. Based on what has been reported to date and on these results, defibrotide should not be considered for the prevention of aGVHD outside clinical trials.

Vitamin E and acute graft‐versus‐host disease after myeloablative allogeneic hematopoietic cell transplantation

2020 ◽  
Author(s):  
Lars Klingen Gjærde ◽  
Sisse Rye Ostrowski ◽  
Lia Minculescu ◽  
Niels Smedegaard Andersen ◽  
Lone Smidstrup Friis ◽  
...  
Keyword(s):  
Vitamin E ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft
Sign in / Sign up

Export Citation Format

Share Document